BD Biosciences, a unit of Becton, Dickinson and Company (BDX), recently launched the BD FACSVerse Flow Cytometer, an expandable, flexible and predictable system, which can analyze as many as 10 parameters and support a wide array of research requirements.
Becton designed the BD FACSVerse System keeping three principles in mind. Firstly, it wanted to provide researchers with one system which would tackle both mundane applications and complicated multi-color experiments. Secondly, the company wanted to simplify workflow and design an easy-to-use system with internal intelligence. Finally, Becton desired to preserve clients’ investments by providing an upgrade mechanism for 10 parameters (versus 6 earlier) besides numerous optional features.
Researchers can utilize the BD FACSuite Software System designed for the BD FACSVerse Flow Cytometer to automate normal tasks, such as instrument startup, setup and data analysis, as well as accomplish others with as few clicks as possible.
The software’s modular design allows users to multi-task, thereby permitting data analysis while, at the same time, the system is gathering data. BD FACSuite Software allows experiments and assays to be transferred to BD FACSVerse Systems based in other locations, thereby reducing frequently seen systemic and user-related divergences.
The BD FACSVerse Flow Cytometer comes with its own intelligence that is designed to increase efficiency, cut down mistakes, automate processes and reduce interaction with users. For example, it has a vacuum-based fluidic component, which permits flexibility when introducing samples.
The BD FACSVerse Flow Cytometer can now be obtained in different color configurations, such as 4-color, 6-color and 8-color setups, with forward-scatter and side-scatter support for as many as 10 parameters. The 4 and 6-color setups are expandable with upgrades. The system comes in a compact size which allows it to easily fit into standard lab bench tops.
We remain cautious about Becton Dickinson due to a lack of major short-term catalysts. The rising demand for safety-needle products (with higher price points and margins) was the primary driver of the company’s past growth, which is not expected to continue, given that the U.S. market is already largely penetrated.
On the positive side, Becton Dickinson’s preeminent global healthcare products franchise is partly insulated from volatile macroeconomic conditions and structural deficiencies elsewhere in the healthcare delivery field.
Becton Dickinson faces a wide range of competitors, including Baxter International (BAX) in certain niches, in each of its three business segments. We currently have a long-term Neutral recommendation on the stock, backed by a short-term Zacks #3 Rank (Hold).
BAXTER INTL (BAX): Free Stock Analysis Report
Be the first to comment